Botox Bladder Injections

Overactive Bladder

Overactive bladder is a condition where your bladder contracts before it is full or when one is not ready. This could mean not being able to hold on until you get to the toilet and at times you may leak urine on the way.

Botox Treatment for Overactive Bladder

Botulinum toxin A or a Botox Injection is a drug more well known for wrinkle treatment, is also used in the treatment of Overactive Bladder (OAB).

Botox is a natural, purified protein which has the ability to relax muscles. It works on the bladder nerves to relax the bladder, helping to:

Your relaxed bladder muscles reduce OAB symptoms like;

  • bladder contractions (spasms),
  • the occurrence of urine leakage,
  • the feeling of needing to go to the toilet very suddenly, and
  • how often you feel the need to pass urine.

How Botox is Administered

Botox treatment is administered as a day procedure. The Botox is injected in tiny amounts into the muscle of the bladder. The whole procedure is very quick and after the treatment, the bladder should be emptied and you are then discharged.

Efficacy of Botox Treatment for Overactive Bladder

Botox does not work immediately but begins to work over several days to two weeks. It is also not a permanent solution, it will last to about 6-8 months. Some women only need a single treatment while others require repeated treatments.

Risk with Botox Treatment

Sometimes Botox works too well, and the bladder has difficulty emptying. In rare occasions it may require a doctor to pass a catheter into the bladder in order to empty it and can last until the Botox wears off.

If you are experiencing symptoms for overactive bladder it you would be advised to see your general practitioner and possibly obtain a referral to see Dr Gailani at www.omargailani.com.au

Botox Treatment for Incontinence

Botox Treatment can be an effective solution to eliminate or reduce overactive bladder symptoms if other medical treatments were not successful.

What is BOTOX Treatment

Botox is a natural, purified protein has the ability to relax muscles. The treatment helps to reduce bladder contractions, the occurrence of urine leakage and the feeling of needing to urinate.

BOTOX treatment can be done in the comfort and privacy of Dr Gailani's treatment rooms with no need for general anaesthetics.

Botox Improves Urinary Incontinence

Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study

Purpose: These are the final results of the prospective, multicenter, long-term (3.5-year) study of the efficacy/safety of onabotulinumtoxinA for overactive bladder syndrome.

Materials and Methods: Patients who completed either of 2, 24-week phase 3 trials could enter a 3-year extension and continue treatment with onabotulinumtoxinA 100 U as needed to control overactive bladder symptoms. Data were analyzed by the treatment(s) received (up to 6) and in discrete subgroups that received 1, 2, 3, 4, 5 or 6 treatments (to evaluate the consistency of the response after repeat treatments in the same patient groups). Assessments included the change from baseline in the number of urinary incontinence episodes per day and the proportion of patients who reported improvement/great improvement in urinary symptoms on the TBS (Treatment Benefit Scale) at week 12 as coprimary end points. Other end points were the change from baseline in 1-QOL (Incontinence Quality of Life), the number of urgency and micturition episodes per day; duration of effect; the number of adverse events; and the initiation of intermittent catheterization.

Results: Consistent mean reductions in urinary incontinence were observed following continued onabotulinumtoxinA treatment, ranging from -3.1 to -3.8 in the overall population and -2.9 to - 4.5 in the discrete subgroups. Durable improvements were seen in overactive bladder symptoms and quality of life. A high proportion of patients rated their condition as improved/greatly improved.

The median duration of effect was 7.6 months. The most common adverse event.